MRK US58933Y1055

Report

Real-time Estimate Cboe BZX - 04:32:22 2023-01-30 pm EST
106.12	USD		+0.70%

12:25p	AstraZeneca Doses First Patient in Phase 3 Study of Datopotamab Deruxtecan to Treat Lung Cancer	MT
11:36a	Daiichi begins Tropion-Lung07 phase 3 trial for lung cancer treatment	AN
09:24a	Merck - FDA Approves KEYTRUDA as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients with Stage IB, II, or IIIA Non-Small Cell Lung Cancer	AQ

Merck Eyes Expanded Blood Disorder Drug Pipeline Via $1.35 Billion Buyout of Imago BioSciences

11/21/2022 | 12:35pm EST

	Stocks mentioned in the article	Change	Last		1st jan.
	MERCK & CO., INC.	0.67%	106.09		-5.02%

All news about MERCK & CO., INC.

12:25p	AstraZeneca Doses First Patient in Phase 3 Study of Datopotamab Deruxtecan to Treat Lun..	MT
11:36a	Daiichi begins Tropion-Lung07 phase 3 trial for lung cancer treatment	AN
09:24a	Merck - FDA Approves KEYTRUDA as Adjuvant Treatment Following Surgical Resection and Pl..	AQ
08:01a	Berenberg Bank Adjusts Merck & Company Price Target to $125 From $115, Maintains Buy Ra..	MT
01/27	Merck Says Keytruda Approved by FDA as Adjuvant Treatment for Non-Small Cell Lung Cance..	MT
01/27	FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resecti..	BU
01/27	Merck Announces the U.S. Food and Drug Administration has Approved KEYTRUDA	CI
01/26	Merck & Co.'s Animal Health Unit Wins US FDA Nod for Expanded Use of Flea Drug for Dogs	MT
01/26	Merck Animal Health Division Says US FDA Approves Expanded Indication of Bravecto Chews..	MT
01/26	Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO (flu..	BU

Analyst Recommendations on MERCK & CO., INC.

08:01a	Berenberg Bank Adjusts Merck & Company Price Target to $125 From $115, Maintains Buy Ra..	MT
01/23	SVB Securities Adjusts Merck & Co.'s Price Target to $120 From $112, Keeps Outperform R..	MT
01/04	BofA Securities Upgrades Merck & Co. to Buy From Neutral, Adjusts Price Target to $130 ..	MT

Financials (USD)

Chart MERCK & CO., INC.

Duration : Period :

Technical analysis trends MERCK & CO., INC.

	Short Term	Mid-Term	Long Term
Trends	Bearish	Bullish	Bullish

Income Statement Evolution

More Financials

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Robert M. Davis	Chairman & chief executive officer
Caroline A. Litchfield	Chief Financial Officer & Executive Vice President
Dave Williams	EVP, Chief Information & Digital Officer
Lisa LeCointe-Cephas	Chief Ethics & Compliance Officer, SVP
Thomas Henry Glocer	Lead Independent Director

Sector and Competitors

		1st jan.	Capi. (M$)
	MERCK & CO., INC.	-5.02%	267 180

MERCK & CO., INC.